Skip to main content
On December 6, 2019, the U.S. Food and Drug Administration (FDA) released a public safety notice on exosome products due to multiple reports of serious adverse effects experienced by individuals in Nebraska who were treated with unapproved products marketed as containing exosomes. The public safety notice asserts that there are currently no FDA-approved exosome products and clinics offering such products outside of FDA's review process are taking advantage of consumers and pose significant harm . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase A Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!

Close

Support Request

Need help now?

Call our toll-free phone number 877-350-6463